Gilead Sciences (NASDAQ:GILD – Get Rating) is scheduled to issue its quarterly earnings data after the market closes on Thursday, April 28th. Analysts expect the company to announce earnings of $1.73 per share for the quarter. Gilead Sciences has set its FY22 guidance at $6.20-6.70 EPS.Parties interested in registering for the company’s conference call can do so using this link.
Gilead Sciences (NASDAQ:GILD – Get Rating) last posted its quarterly earnings results on Tuesday, February 1st. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.53 by ($0.84). Gilead Sciences had a return on equity of 45.27% and a net margin of 22.80%. The firm had revenue of $7.24 billion for the quarter, compared to the consensus estimate of $6.64 billion. During the same period last year, the company posted $2.19 earnings per share. The business’s revenue was down 2.4% compared to the same quarter last year. On average, analysts expect Gilead Sciences to post $7 EPS for the current fiscal year and $6 EPS for the next fiscal year.
NASDAQ GILD opened at $63.60 on Thursday. Gilead Sciences has a 1 year low of $57.19 and a 1 year high of $74.12. The firm has a market capitalization of $79.75 billion, a P/E ratio of 12.90, a price-to-earnings-growth ratio of 0.44 and a beta of 0.40. The firm’s fifty day moving average price is $60.47 and its two-hundred day moving average price is $65.96. The company has a current ratio of 1.27, a quick ratio of 1.13 and a debt-to-equity ratio of 1.24.
Several equities analysts have commented on the stock. Maxim Group decreased their price objective on shares of Gilead Sciences from $88.00 to $84.00 in a report on Thursday, February 3rd. Morgan Stanley decreased their price objective on shares of Gilead Sciences from $69.00 to $63.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 12th. Bank of America decreased their price objective on shares of Gilead Sciences from $73.00 to $71.00 and set a “neutral” rating on the stock in a report on Wednesday, February 2nd. BMO Capital Markets assumed coverage on shares of Gilead Sciences in a report on Tuesday, March 8th. They issued a “hold” rating and a $65.00 price objective on the stock. Finally, Barclays decreased their price objective on shares of Gilead Sciences from $63.00 to $56.00 and set an “underweight” rating on the stock in a report on Thursday, March 10th. One analyst has rated the stock with a sell rating, nine have given a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Gilead Sciences has an average rating of “Hold” and a consensus target price of $73.31.
In other news, EVP Brett A. Pletcher sold 3,634 shares of the stock in a transaction dated Friday, March 11th. The shares were sold at an average price of $58.24, for a total value of $211,644.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Brett A. Pletcher sold 1,691 shares of the stock in a transaction dated Wednesday, February 9th. The stock was sold at an average price of $63.89, for a total transaction of $108,037.99. The disclosure for this sale can be found here. Insiders have sold 19,386 shares of company stock worth $1,283,423 over the last quarter. Corporate insiders own 0.16% of the company’s stock.
Several hedge funds have recently bought and sold shares of GILD. First Community Trust NA bought a new position in shares of Gilead Sciences in the fourth quarter worth about $34,000. EverSource Wealth Advisors LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth about $76,000. Levin Capital Strategies L.P. bought a new position in shares of Gilead Sciences in the fourth quarter worth about $203,000. Titleist Asset Management LTD. bought a new position in shares of Gilead Sciences in the fourth quarter worth about $208,000. Finally, Privium Fund Management UK Ltd bought a new position in shares of Gilead Sciences in the fourth quarter worth about $210,000. 79.00% of the stock is owned by hedge funds and other institutional investors.
Gilead Sciences Company Profile (Get Rating)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.
- Get a free copy of the StockNews.com research report on Gilead Sciences (GILD)
- 3 Ways to Invest in 5G Growth
- Sell-Side Activity Drives Proctor & Gamble Higher
- Google Upgraded Ahead Of Earnings
- Highly Valued Abbot Laboratories Could Move Lower
- Baker Hughes, Another Buy-The-Dip Opportunity In Oilfield Services
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.